Back to Results
First PageMeta Content
Merck KGaA / Pharmacology / Serono / Merck & Co. / Serostim / Kommanditgesellschaft auf Aktien / Interferon beta-1a / Merck Manual of Diagnosis and Therapy / Genset Corporation / Merck / Pharmaceutical industry / Pharmaceutical sciences


News Release June 8, 2011 Affectis Pharmaceuticals and Merck Serono Announce an Agreement to Develop Oral Drugs for Neurodegenerative Diseases Merck Serono to develop compounds from Affectis targeting P2X7 receptors
Add to Reading List

Document Date: 2011-06-14 06:59:15

Open Document

File Size: 139,18 KB

Share Result on Facebook

City

Geneva / Martinsried / Munich / Darmstadt / /

Company

Merck & Co. / Affectis Pharmaceuticals AG / Global Research / Merck Serono / Merck KGaA / Contact Affectis Pharmaceuticals AG / /

Country

Switzerland / Germany / United States / Canada / /

Currency

EUR / /

/

Event

Business Partnership / Funding / /

Facility

Max Planck Institute of Psychiatry / /

IndustryTerm

chemical and biological origin / treatment of psychiatric and neuroinflammatory disorders / pharmaceutical / treatment of central nervous system diseases / biopharmaceutical company developing novel drugs / prescription medicines / biopharmaceutical division / chemical / /

MedicalCondition

endocrine and metabolic disorders / multiple sclerosis / infertility / cancer / psychiatric and neuroinflammatory disorders / cardiometabolic diseases / neurodegenerative diseases / depression / /

Organization

Max Planck Institute of Psychiatry / /

Person

Michael Boes / Bernhard Kirschbaum / Manfred Ruediger / Luc St-Onge / /

/

Position

Chief Scientist Officer / Chief Executive Officer / Executive Vice President / /

Product

Serostim / Gonal-f / Rebif / Kuvan / Glucophage / Saizen / Erbitux / /

Technology

drug discovery / /

URL

www.merck.de / www.merckserono.com / www.affectis.com / /

SocialTag